The Clinical Research Services (CRS) was established in December 1986 as a shared resource to facilitate development, implementation, and completion of all UPCI clinical research studies. CRS provides study development and implementation assistance, IRB processing, patient recruitment, study coordination, and specimen and data collection for all investigators conducting cancer-related studies at all UPMC Cancer Centers. The University of Pittsburgh Cancer Institute (UPCI) recently reorganized its clinical research organization to be in a better position to rapidly implement clinical trials and to comply with the more stringent regulatory requirements. To achieve these goals, additional infrastructure has been developed, to ensure timely review by the regulatory bodies, review by legal counsel for both UPMC and the University of Pittsburgh, budgetary negotiations with sponsors, and financial review of all aspects of the clinical trial. CRS facilitates IRB review of all clinical research studies approvcd by the PRC, and for which needed resources are allocated. The CRS database maintains up to date on the status of each study, including timely submission of all required documents and amendments to the IRB, study renewal forms, progress reports, Data Safety Monitoring information, Serious Adverse Events, monthly reports, IRB and other correspondences.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-19
Application #
7279244
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
19
Fiscal Year
2006
Total Cost
$206,448
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Redner, Robert L; Beumer, Jan H; Kropf, Patricia et al. (2018) A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leuk Lymphoma 59:2595-2601
Ancevski Hunter, Katerina; Socinski, Mark A; Villaruz, Liza C (2018) PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22:1-10
Luu, Thehang; Kim, Kyu-Pyo; Blanchard, Suzette et al. (2018) Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer. Breast Cancer Res Treat 167:469-478
Menk, Ashley V; Scharping, Nicole E; Moreci, Rebecca S et al. (2018) Early TCR Signaling Induces Rapid Aerobic Glycolysis Enabling Distinct Acute T Cell Effector Functions. Cell Rep 22:1509-1521
Shiffman, Saul; Scholl, Sarah M (2018) Three approaches to quantifying cigarette consumption: Data from nondaily smokers. Psychol Addict Behav 32:249-254
Shayan, Gulidanna; Kansy, Benjamin A; Gibson, Sandra P et al. (2018) Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res 24:62-72
Frahm, Krystle A; Waldman, Jacob K; Luthra, Soumya et al. (2018) A comparison of the sexually dimorphic dexamethasone transcriptome in mouse cerebral cortical and hypothalamic embryonic neural stem cells. Mol Cell Endocrinol 471:42-50
Pulopulos, Matias M; Vanderhasselt, Marie-Anne; De Raedt, Rudi (2018) Association between changes in heart rate variability during the anticipation of a stressful situation and the stress-induced cortisol response. Psychoneuroendocrinology 94:63-71
Moravcikova, Erika; Meyer, E Michael; Corselli, Mirko et al. (2018) Proteomic Profiling of Native Unpassaged and Culture-Expanded Mesenchymal Stromal Cells (MSC). Cytometry A 93:894-904
Samuelsson, Laura B; Bovbjerg, Dana H; Roecklein, Kathryn A et al. (2018) Sleep and circadian disruption and incident breast cancer risk: An evidence-based and theoretical review. Neurosci Biobehav Rev 84:35-48

Showing the most recent 10 out of 1187 publications